Un equilibrio. El equilibrio se define de diversos modos. Se trata de un equilibrio entre los derechos privados (incentivos para crear) y el interés público (posibilidad de utilizar o acceder a las creaciones). También se trata de un equilibrio entre el corto y el largo plazo.
- Largo plazo: la sociedad se beneficia de las creaciones y de las invenciones, incluso cuando el período de protección termina y pasan al dominio público
- Corto plazo: la protección de la propiedad intelectual está en su mayor parte limitada en el tiempo -salvo excepciones-. Normalmente, los derechos privados se protegen a corto plazo como incentivo para crear e inventar. Cuando la protección de la propiedad intelectual supone costes sociales, los gobiernos pueden cumplir sus objetivos de bienestar y desarrollo social ajustando la protección mediante diversas excepciones y formas de flexibilidad, por ejemplo para hacer frente a problemas de salud pública
Transferencia de tecnología. La protección de la propiedad intelectual debe contribuir a la innovación técnica y la transferencia de tecnología. Debe beneficiar tanto a los productores como a los usuarios, así como a las economías y las sociedades en general.
Igualdad de trato.
Diferentes sistemas jurídicos …. El Acuerdo sobre los ADPIC respeta los sistemas jurídicos de los distintos Miembros, que pueden diferir considerablemente. Cada Miembro puede decidir la forma en que protegerá la propiedad intelectual y aplicará las disposiciones del Acuerdo, siempre que cumpla las normas mínimas del Acuerdo sobre los ADPIC (véase el paragraph 1 of Article 1).
- Trato nacional — tratar por igual a los nacionales del país y a los extranjeros, con excepciones limitadas
- Trato de la nación más favorecida — igualdad de trato para los nacionales de todos los interlocutores comerciales Miembros de la OMC, con excepciones limitadas
… same minimum standards. Countries have to meet minimum standards set by the TRIPS Agreement, such as the minimum number of years of protection. Each country is also free set its own standards at a higher level than the agreement requires, sometimes called “TRIPS-plus”, so long as this is consistent with the agreement. (See paragraph 1 of Article 1).
Some current issues
Briefly, these are some of the issues currently or recently discussed in the TRIPS Council. Some are regularly on the agenda; others are raised from time to time. More details at www.wto.org/trips#issues.
TRIPS and public health
www.wto.org/tripshealth and fact sheet
No conflict. The 2001 Doha Declaration on TRIPS and Public Health was a political statement affirming that intellectual property protection and public health objectives do not contradict each other: “We agree that the TRIPS Agreement does not and should not prevent members from taking measures to protect public health.”
It gave governments the confidence to use the flexibilities available in the TRIPS Agreement. For example: compulsory licensing and parallel imports (see jargon buster).
Rule-change needed: the “paragraph 6 system”. One issue needed a change in the rules. The declaration’s paragraph 6 dealt with TRIPS Article 31(f), which limited the amount nations could export under a compulsory licence to countries needing the medicines. A “waiver” agreed in 2003, and a pending amendment agreed in 2005, allow generic medicines to be made under compulsory licences exclusively for export to countries that cannot produce the medicines themselves. This “Par.6 system” is routinely reviewed in the TRIPS Council.
WHO-WIPO-WTO cooperation. An important result of the 2001 declaration has been closer work between the World Health Organization, World Intellectual Property Organization and WTO. This has focused both on access to medicines and on incentives for research and development so that new medical technologies become available. It has underscored the fact that intellectual property is only part of the picture. Ensuring poorer patients are able to access medicines and other health products,, involves proper (“rational”) use of the products, affordable prices, properly designed health systems, suitable financing, and carefully selecting strategies for procuring the products.
TRIPS, biodiversity, traditional knowledge, plants and life forms
See www.wto.org/tripsbio and explanation
In the TRIPS Council, these topics are usually discussed under three merged agenda items — a “triplet” of related issues. They come under the Doha Development Agenda although members disagree on whether they are negotiations. These issues are also discussed in separate consultations chaired by the Director-General or a deputy.
- Animals and plants. TRIPS Art.27.3(b) deals with patentability or non-patentability of plant and animal inventions, and the protection of plant varieties. It has been under review in the TRIPS Council for several years. The Doha Declaration added:
- TRIPS and CBD — the relationship between the TRIPS Agreement and the UN Convention on Biological Diversity
- Traditional knowledge — the protection of traditional knowledge and folklore
The TRIPS Council’s review of the three is guided by the TRIPS Agreement’s objectives (Article 7 which says the objective is innovation and technology transfer for social and economic benefits) and principles (Article 8, which refers to health and other social and economic objectives, and to abuse of rights), and must take development fully into account.
Members agree on the objectives:
- the need to avoid inappropriate patenting, such as patenting a claimed invention that is not new or does not involve an “inventive step”
- the need to avoid what is sometimes loosely called “biopiracy”. This is the unauthorized use of genetic resources or traditional knowledge (as laid down in the international treaty on biodiversity), ie, without the permission of the countries or communities considered to be the rightful owners — complex concepts that are still being debated
They disagree about how to achieve this. One proposal would amend the TRIPS Agreement so that patent applicants are required to disclose the origin of genetic resources and any traditional knowledge used in the inventions. This “disclosure” would avoid inappropriate patenting and provide evidence that the patent applicants received “prior informed consent” (a term used in the UN Convention on Biological Diversity), and evidence of “fair and equitable” benefit sharing. Others envisage some other forms of disclosure.
Some advocate other ways of achieving these objectives without amending the TRIPS Agreement and without “disclosure”. These include contracts with whoever is considered to be the rightful owner, and databases that patent examiners can use to avoid bad patenting.
Some countries oppose patenting all life forms outright, meaning patenting would not be possible at all and disclosure would not be relevant.
See www.wto.org/gi and explanation
Geographical indications are place names (in some countries also words associated with a place) used to identify the origin and quality, reputation or other characteristics of products (for example, “Champagne”, “Tequila” or “Roquefort”).
The TRIPS Agreement handles this in three articles.
- Standard: Article 22 defines geographical indications and sets a standard level of protection. All have to be protected in order to avoid misleading the public and to prevent unfair competition
- Higher: Article 23 applies only to protection for wines and spirits and says that subject to a number of exceptions their names have to be protected against incorrect use even where this would not mislead the public
- Exceptions: Article 24. For example, a term does not have to be protected in a country if it has become generic or has already been protected as a trademark in that country
Two issues are debated in the TRIPS Council under the Doha mandate: negotiations to create a multilateral geographical indications register for wines and spirits; and discussions on extending the higher (Article 23) level of protection beyond wines and spirits.
See coverage and explanation
WTO agreements allow countries to bring cases against each other if one feels that another government’s action or a specific situation has deprived it of an expected benefit, even if no agreement has been violated.
But opinions differ among WTO members on whether non-violation cases are feasible in intellectual property. The TRIPS Agreement contains a temporary restraint (a “moratorium”, Article 64.2) on bringing non-violation complaints. This has been extended several times, more recently from one Ministerial Conference to the next.
Developingand least developed countries, in particular, see technology transfer as part of the bargain in which they have agreed to protect intellectual property rights. The TRIPS Agreement includes a number of provisions on this. For example, it says one of the purposes of protecting intellectual property is to promote innovation and technology transfer, and it requires developed countries’ governments to provide incentives for their companies and institutions to transfer technology to least-developed countries (Article 66.2). More here
Least developed countries’ priority needs
As least developed countries use their transition period to prepare to implement the WTO’s intellectual property provisions, they have been asked to identify their needs in order to receive support. An overview of the process of identifying and responding to least developed countries’ needs, with links to working materials, updates and tools for coordinating this on-going work can be found here.
Intellectual property rights have to be enforceable. Or, more precisely, the TRIPS Agreement says governments have to provide effective procedures for enforcement. The question of discussing enforcement routinely in the TRIPS Council has sometimes been controversial.
Some developed countries considered counterfeiting and piracy to be a serious problem and wanted to discuss it; developing countries resisted, fearing that this would target them and be used to argue for new standards more stringent than those in TRIPS.
Recently (around 2011) the discussion has focused on an Anti-Counterfeiting Trade Agreement (ACTA) negotiated by a group of countries (text in document IP/C/W/563). The ACTA countries said the opposition to undertaking work on enforcement in the WTO was one reason why they negotiated the agreement outside the WTO.
A number of developing countries said they were concerned about the possibility that access to medicines could be impeded, that pressure would increase on countries to protect intellectual property to a higher standard than required in the WTO (the ACTA countries said they would not), and about the implications for the WTO system of discussing an agreement negotiated outside the WTO. (See TRIPS news.)